» Articles » PMID: 29206153

Is Genetic Mobilization Considered When Using Bacteriophages in Antimicrobial Therapy?

Overview
Specialty Pharmacology
Date 2017 Dec 6
PMID 29206153
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The emergence of multi-drug resistant bacteria has undermined our capacity to control bacterial infectious diseases. Measures needed to tackle this problem include controlling the spread of antibiotic resistance, designing new antibiotics, and encouraging the use of alternative therapies. Phage therapy seems to be a feasible alternative to antibiotics, although there are still some concerns and legal issues to overcome before it can be implemented on a large scale. Here we highlight some of those concerns, especially those related to the ability of bacteriophages to transport bacterial DNA and, in particular, antibiotic resistance genes.

Citing Articles

Re-Emergence of Bacteriophages and Their Products as Antibacterial Agents: An Overview.

Kalia V, Patel S, Gong C, Lee J Int J Mol Sci. 2025; 26(4).

PMID: 40004222 PMC: 11855700. DOI: 10.3390/ijms26041755.


Alternative therapeutic strategies to treat antibiotic-resistant pathogens.

MacNair C, Rutherford S, Tan M Nat Rev Microbiol. 2023; 22(5):262-275.

PMID: 38082064 DOI: 10.1038/s41579-023-00993-0.


The promising role of bacteriophage therapy in managing total hip and knee arthroplasty related periprosthetic joint infection, a systematic review.

Khalifa A, Hussien S J Exp Orthop. 2023; 10(1):18.

PMID: 36786898 PMC: 9929010. DOI: 10.1186/s40634-023-00586-z.


Natural Killers: Opportunities and Challenges for the Use of Bacteriophages in Microbial Food Safety from the One Health Perspective.

Lavilla M, Domingo-Calap P, Sevilla-Navarro S, Lasagabaster A Foods. 2023; 12(3).

PMID: 36766081 PMC: 9914193. DOI: 10.3390/foods12030552.


Modelling the synergistic effect of bacteriophage and antibiotics on bacteria: Killers and drivers of resistance evolution.

Leclerc Q, Lindsay J, Knight G PLoS Comput Biol. 2022; 18(11):e1010746.

PMID: 36449520 PMC: 9744316. DOI: 10.1371/journal.pcbi.1010746.


References
1.
Quiros P, Colomer-Lluch M, Martinez-Castillo A, Miro E, Argente M, Jofre J . Antibiotic resistance genes in the bacteriophage DNA fraction of human fecal samples. Antimicrob Agents Chemother. 2013; 58(1):606-9. PMC: 3910789. DOI: 10.1128/AAC.01684-13. View

2.
Schmelcher M, Donovan D, Loessner M . Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012; 7(10):1147-71. PMC: 3563964. DOI: 10.2217/fmb.12.97. View

3.
Zinder N . Bacterial transduction. J Cell Physiol Suppl. 1955; 45(Suppl. 2):23-49. DOI: 10.1002/jcp.1030450504. View

4.
Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A . Engineered endolysin-based "Artilysins" to combat multidrug-resistant gram-negative pathogens. mBio. 2014; 5(4):e01379-14. PMC: 4161244. DOI: 10.1128/mBio.01379-14. View

5.
Roach D, Donovan D . Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage. 2015; 5(3):e1062590. PMC: 4590002. DOI: 10.1080/21597081.2015.1062590. View